Big Pharma execs renew commitment to China at import expo by Angus Liu Wednesday, November 6, 2019 Executives from AstraZeneca, Roche, Sanofi and GSK showcased investments in China as the country continues revamping its drug buying and regulation.
FDA: Zantac carcinogens no more dangerous than 'grilled meats' by Kyle Blankenship Monday, November 4, 2019 Worried about "unacceptable levels" of a carcinogen in your Zantac? Don't worry, the FDA said, the levels were no higher than those in grilled meats.
GSK leans on respiratory franchise with Trelegy share-grab by Kyle Blankenship Wednesday, October 30, 2019 Thanks to a market-share grab for triple-drug COPD therapy Trelegy Ellipta, GSK's respiratory strategy is working as planned.
Pfizer, GSK and more strike $248M deal in Medicaid fraud suit by Kyle Blankenship Tuesday, October 29, 2019 After 14 years of litigation, a slew of drugmakers are finally settling a protracted battle over claims they defrauded Illinois' Medicaid program.
Awareness: 'Breath of Life' by Beth Snyder Bulik Beauty, creativity, cultural relevance and technology roll up together in the awareness award winner “Breath of Life” from GlaxoSmithKline and McCann Health.
GSK offers makeovers and more for women living with lupus by Beth Snyder Bulik Wednesday, October 30, 2019 GSK is extending its "Night of Beauty" events at Sephora stores to offer education and makeovers to women of color who are living with lupus.
GSK nabs expanded Zejula ovarian cancer nod by Angus Liu Thursday, October 24, 2019 GSK’s Zejula has opened up a new front in its challenge against AstraZeneca and Merck’s Lynparza, the established leader in the PARP class.
Pfizer, GSK, others face Zantac carcinogen testing lawsuits by Kyle Blankenship Wednesday, October 23, 2019 GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.
GSK sells 2 vaccines to Bavarian Nordic in $1.1B deal by Eric Sagonowsky Monday, October 21, 2019 Several of GlaxoSmithKline's vaccines are riding strong momentum and now the drugmaker is selling two assets to focus on those growth products.
GSK joins other drugmakers recalling Zantac products by Eric Palmer Wednesday, October 9, 2019 GlaxoSmithKline has decided its time to pull its ranitidine heartburn meds off the shelves in markets where it sells them.
